|
Hemato-oncology
Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study
Dong Won Baek, Han-Seung Park, Sang Kyun Sohn, Dae Young Kim, Inho Kim, Jae-Sook Ahn, Young Rok Do, Se Ryeon Lee, Hyeon-Seok Eom, Won-Sik Lee, Sung-Hyun Kim, Ho Sup Lee, Yoo Jin Lee, Joon Ho Moon, Je-Hwan Lee; Adult Acute Lymphoblastic Leukemia Working Party, the Korean Society of Hematology
Korean J Intern Med. 2023;38(5):734-746. Published online June 20, 2023
Background/Aims: We performed a prospective study to determine the efficacy and safety of rituximab including chemotherapy in CD20-positive acute lymphoblastic leukemia (ALL).
Methods: Patients with newly diagnosed ALL, aged ≥ 15 years, were eligible for the study if their leukemic blast cells in ..
|
|
|
Mixed-phenotype acute leukemia treated with decitabine
Ji-Young Lee, Sang-min Lee, Ja-Young Lee, Ki-Hyang Kim, Moon-Young Choi, Won-Sik Lee
Korean J Intern Med. 2016;31(2):406-408. Published online February 15, 2016
|
|
|
Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
Ki-Hyang Kim, Young-Don Joo, Chang-Hak Sohn, Ho-Jin Shin, Joo-Seop Chung, Goon-Jae Cho, Sung-Hoon Shin, Yang-Soo Kim, Won-Sik Lee
Korean J Intern Med. 2009;24(1):37-42. Published online March 6, 2009
Background/AimsTo date, an effective salvage chemotherapy regimen for the treatment of refractory or relapsing non-Hodgkin's lymphoma (NHL) has not been discovered. This study was conducted to evaluate the efficacy and safety of gemcitabine, etoposide, cisplatin, and dexametha..
|
|
|
